F
Fabian Kratochwil
Researcher at German Cancer Research Center
Publications - 3
Citations - 1726
Fabian Kratochwil is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Bisulfite sequencing & Atypical teratoid rhabdoid tumor. The author has an hindex of 3, co-authored 3 publications receiving 1327 citations.
Papers
More filters
Journal ArticleDOI
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups
Kristian W. Pajtler,Kristian W. Pajtler,Hendrik Witt,Martin Sill,David T.W. Jones,Volker Hovestadt,Fabian Kratochwil,Khalida Wani,Ruth G. Tatevossian,Chandanamali Punchihewa,Pascal Johann,Jüri Reimand,Hans-Jörg Warnatz,Marina Ryzhova,Steve Mack,Vijay Ramaswamy,David Capper,David Capper,Leonille Schweizer,Leonille Schweizer,Laura Sieber,Andrea Wittmann,Zhiqin Huang,Peter van Sluis,Richard Volckmann,Jan Koster,Rogier Versteeg,Daniel W. Fults,Helen Toledano,Smadar Avigad,Lindsey M. Hoffman,Andrew M. Donson,Nicholas K. Foreman,Ekkehard Hewer,Karel Zitterbart,Mark R. Gilbert,Terri S. Armstrong,Terri S. Armstrong,Nalin Gupta,Jeffrey C. Allen,Matthias A. Karajannis,David Zagzag,Martin Hasselblatt,Andreas E. Kulozik,Olaf Witt,V. Peter Collins,Katja von Hoff,Stefan Rutkowski,Torsten Pietsch,Gary D. Bader,Marie-Laure Yaspo,Andreas von Deimling,Andreas von Deimling,Peter Lichter,Michael D. Taylor,Richard J. Gilbertson,David W. Ellison,Kenneth Aldape,Andrey Korshunov,Andrey Korshunov,Marcel Kool,Stefan M. Pfister +61 more
TL;DR: The molecular classification proposed herein outperforms the current histopathological classification and thus might serve as a basis for the next World Health Organization classification of CNS tumors.
Journal ArticleDOI
Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma
Paul A. Northcott,Catherine A. Lee,Catherine A. Lee,Thomas Zichner,Adrian M. Stütz,Serap Erkek,Daisuke Kawauchi,David Shih,Volker Hovestadt,Marc Zapatka,Dominik Sturm,David T.W. Jones,Marcel Kool,Marc Remke,Florence M.G. Cavalli,Scott Zuyderduyn,Gary D. Bader,Scott R. VandenBerg,Lourdes Adriana Esparza,Marina Ryzhova,Wei Wang,Andrea Wittmann,Sebastian Stark,Laura Sieber,Huriye Seker-Cin,Linda Linke,Fabian Kratochwil,Natalie Jäger,Ivo Buchhalter,Charles D. Imbusch,Gideon Zipprich,Benjamin Raeder,Sabine Schmidt,Nicolle Diessl,Stephan Wolf,Stefan Wiemann,Benedikt Brors,Chris Lawerenz,Jürgen Eils,Hans-Jörg Warnatz,Thomas Risch,Marie-Laure Yaspo,Ursula D. Weber,Cynthia C. Bartholomae,Christof von Kalle,Eszter Turányi,Peter Hauser,Emma Sandén,Anna Darabi,Peter Siesjö,Jaroslav Sterba,Karel Zitterbart,David Sumerauer,Peter van Sluis,Rogier Versteeg,Richard Volckmann,Jan Koster,Martin U. Schuhmann,Martin Ebinger,H. Leighton Grimes,Giles W. Robinson,Amar Gajjar,Martin Mynarek,Katja von Hoff,Stefan Rutkowski,Torsten Pietsch,Wolfram Scheurlen,Jörg Felsberg,Guido Reifenberger,Andreas E. Kulozik,Andreas von Deimling,Olaf Witt,Roland Eils,Richard J. Gilbertson,Andrey Korshunov,Michael D. Taylor,Peter Lichter,Jan O. Korbel,Robert J. Wechsler-Reya,Stefan M. Pfister +79 more
TL;DR: GFI1 and GFI1B are identified as prominent medulloblastoma oncogenes and ‘enhancer hijacking’ is implicate as an efficient mechanism driving oncogene activation in a childhood cancer.
Journal ArticleDOI
Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes
Pascal Johann,Pascal Johann,Serap Erkek,Marc Zapatka,Kornelius Kerl,Ivo Buchhalter,Volker Hovestadt,David T.W. Jones,Dominik Sturm,Dominik Sturm,Carl Hermann,Maia Segura Wang,Andrey Korshunov,Andrey Korshunov,Marina Rhyzova,Susanne Gröbner,Sebastian Brabetz,Lukas Chavez,Susanne Bens,Stefan Gröschel,Fabian Kratochwil,Andrea Wittmann,Laura Sieber,Christina Geörg,Stefan Wolf,Katja Beck,Florian Oyen,David Capper,David Capper,Peter van Sluis,Richard Volckmann,Jan Koster,Rogier Versteeg,Andreas von Deimling,Andreas von Deimling,Till Milde,Till Milde,Olaf Witt,Olaf Witt,Andreas E. Kulozik,Martin Ebinger,Tarek Shalaby,Michael A. Grotzer,David Sumerauer,Josef Zamecnik,Jaume Mora,Nada Jabado,Michael D. Taylor,Annie Huang,Eleonora Aronica,Anna Marta Maria Bertoni,Bernhard Radlwimmer,Torsten Pietsch,Ulrich Schüller,Reinhard Schneppenheim,Paul A. Northcott,Jan O. Korbel,Reiner Siebert,Michael C. Frühwald,Michael C. Frühwald,Peter Lichter,Roland Eils,Amar Gajjar,Martin Hasselblatt,Stefan M. Pfister,Stefan M. Pfister,Marcel Kool +66 more
TL;DR: Three distinct molecular subgroups of ATRTs, associated with differences in demographics, tumor location, and type of SMARCB1 alterations, were identified, leading to the identification of subgroup-specific regulatory networks and potential therapeutic targets.